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Abstract
Vascular cell adhesion molecule-1 (VCAM-1), an inducible
cell-cell recognition protein on the endothelial cell surface
(EC), has been associated with early stages of atherosclero-
sis. In view of the accelerated vascular disease observed
in patients with diabetes, and the enhanced expression of
VCAM-1 in diabetic rabbits, we examined whether irrevers-
ible advanced glycation endproducts (AGEs), could mediate
VCAM-1 expression by interacting with their endothelial
cell receptor (receptor for AGE, RAGE). Exposure of cul-
tured human ECs to AGEs induced expression of VCAM-
1, increased adhesivity of the monolayer for Molt-4 cells,
and was associated with increased levels of VCAM-1 tran-
scripts. The inhibitory effect of anti-RAGE IgG, a truncated
form of the receptor (soluble RAGE) or N-acetylcysteine
on VCAM-1expression indicated that AGE-RAGE-induced
oxidant stress was central to VCAM-1 induction. Electro-
phoretic mobility shift assays on nuclear extracts from
AGE-treated ECs showed induction of specific DNAbinding
activity for NF-kB in the VCAM-1 promoter, which was
blocked by anti-RAGE IgG or N-acetylcysteine. Soluble
VCAM-1 antigen was elevated in human diabetic plasma.
These data are consistent with the hypothesis that AGE-
RAGEinteraction induces expression of VCAM-1which can
prime diabetic vasculature for enhanced interaction with
circulating monocytes. (J. Clin. Invest. 1995.96:1395-1403.)
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Introduction
Accelerated atherosclerosis and microvascular disease are the
major vascular complications of diabetes, and constitute the
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principal cause of morbidity and mortality in this ubiquitous
disorder (1-2). Many underlying factors could contribute to
this outcome, including abnormalities in plasma lipoproteins,
blood pressure, and renal function. A final commonpathway in
the development of vascular pathology is the expression of
inducible adhesion molecules rendering the vasculature a selec-
tive target for circulating peripheral blood cells. In this context,
vascular cell adhesion molecule-i (VCAM-1)' is of particular
interest as its expression has been linked to the early phase of
experimental hypercholesterolemia-induced atherosclerosis (3-
4), and enhanced vascular VCAM-1 expression has been dem-
onstrated in the vasculature of alloxan-treated diabetic rabbits
(5) as well as in human atherosclerotic lesions (6).
To identify a sustained stimulus for enhanced expression of
VCAM-1 in diabetes, we have considered a potentially etiologic
role for advanced glycation endproducts (AGEs). Exposure of
proteins and lipids to aldoses results in nonenzymatic glycation;
initially forming reversible early glycation products, Schiff
bases, and Amadori products (7), which, after complex molecu-
lar rearrangements, become irreversible AGEs (8-10). The
latter constitute a class of heterogeneous structures of yellow-
brown color, characteristic fluorescence, which form cross-
links, generate reactive oxygen intermediates (ROIs), and inter-
act with particular cellular receptors (8-11). The endothelial
receptor for AGEs, termed RAGE, is a newly identified member
of the immunoglobulin superfamily of cell surface molecules
and has been shown to mediate interactions with these glycated
proteins in vitro and in vivo ( 11 - 14). RAGEis expressed both
in normal (15) and diabetic vasculature (A. M. Schmidt and
D. Stem, unpublished observations).
Since AGEs are found in the plasma and accumulate in the
vessel wall in diabetes, the potential role of interaction of AGEs
with endothelial RAGEin induction of VCAM-1 expression
was examined. Our data indicate that AGEs, either those pre-
pared in vitro or isolated from patients with diabetes, led to
VCAM-1 expression in cultured ECs by a mechanism involving
AGEbinding to RAGElikely as a consequence of induction of
cellular oxidant stress and activation of the transcription factor
NF-kB. Infusion of AGEs into mice also enhanced vascular
VCAM-1 expression, and soluble VCAM-1 antigen was ele-
1. Abbreviations used in this paper: AGE, advanced glycation endpro-
duct; EC, endothelial cell; EMSA, electrophoretic mobility shift assay;
GAPDH, glyceraldehyde phosphate dehydrogenase; MP, mononuclear
phagocyte; NAC, N-acetylcysteine; RAGE, receptor for AGE; ROI,
reactive oxygen intermediate; sRAGE, soluble RAGE; sVCAM-1, solu-
ble VCAM-1; VCAM-1, Vascular Cell Adhesion Molecule-l; VLA-4,
very late antigen 4.
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vated in plasma of patients with diabetes, suggesting increased
VCAM-1 production. These data support the concept of a role
for AGEs in enhanced expression of VCAM-1 in diabetes, and
suggest that this could provide a mechanism for targeting mono-
nuclear phagocytes (MPs) to diabetic vasculature.
Methods
Endothelial cell culture and RAGEblocking reagents. HumanECs were
prepared from umbilical cords, grown in culture as described (16, 17),
and experiments utilized confluent cultures (passages 1-3) grown in
Medium 199 supplemented with fetal bovine serum (15%; Gemini,
Calabasas, CA), human serum (5%; Gemini), endothelial cell growth
supplement (Boehringer Mannheim, Indianapolis, IN), heparin (90 0g/
ml; Sigma Chemical Co., St. Louis, MO)and antibiotics. In most experi-
ments, human umbilical vein endothelial cells (ECs) were used, but
where specifically indicated, certain experiments were performed with
human aortic endothelial cells (Clonetics, San Diego, CA). Confluent
cultures of human aortic endothelial cells were used for experiments at
passages 4-6. RAGEis present on the surface of both human umbilical
vein and human aortic endothelial cells by immunohistochemistry using
previously published methods (15, data not shown). Blockade of EC
RAGEused soluble(s) bovine RAGEand monospecific antibody to
sRAGE. Bovine RAGEwas purified to homogeneity from bovine lung
acetone powder (Sigma Chemical Co.) by the methods previously de-
scribed (12). This material represents the amino-terminal two-thirds of
the molecule based on analysis of tryptic peptides and is called soluble
RAGEor sRAGE. Purified bovine RAGEwas used to immunize rabbits,
according to previously described methods (18), IgG was purified by
affinity chromatography with immobilized protein A, and nonimmune
rabbit IgG was similarly prepared. Immunoblotting studies showed that
anti-RAGE IgG was monospecific; it bound only RAGEand binding
was blocked completely by pre-adsorption with purified RAGE. F(ab' )2
was prepared from IgG with a kit from Pierce (Rockville, IL) according
to the manufacturer's instructions. The final F(ab')2, which was homo-
geneous on SDS PAGE, was then dialyzed extensively versus phos-
phate-buffered saline.
Preparation of glycated proteins and antibodies. Bovine serum albu-
min (fatty acid free; Sigma Chemical Co.) was glycated by incubation
with glucose (0.5 M) at 37°C for 4 wk. Glycated proteins were charac-
terized based on fluorescence, binding to cultured ECs and to purified
RAGE(18). SDS-PAGEshowed a single major band corresponding to
69 kD, and the isoelectric point was largely unchanged (a shift of
< 0.1-0.3 pH units toward acidity was variably noted; characterization
of these glycated albumin preparations has previously been described
in detail [18 ] ). Nonglycated albumin was treated identically as glycated
albumin (i.e., incubation at 37°C for 4 wk) except that no glucose
was present in the reaction mixture. AGEs were immunoisolated from
diabetic serum using affinity-purified anti-AGE IgG, prepared and char-
acterized as described previously (18, 19). This antibody selectively
reacts with AGE-modified forms of proteins, but not native polypeptides,
nor early glycation adducts, or other modifications (formylation, maleyl-
ation, acetylation, or copper oxidation) ( 19). Anti-AGE IgG was immo-
bilized on Affi-Gel 10 (BioRad, Hercules, CA) according to the manu-
facturer's instructions and diabetic serum was applied. The material that
did not adhere to this column, defined as AGE-depleted serum, was
subsequently negative for AGE-immunoreactive material as determined
by AGEELISA which used the above affinity-purified anti-AGE IgG
(18, 19). After collecting the AGE-depleted material, the column was
washed extensively with neutral buffer and eluted with high salt (NaCl,
2 M) as described ( 18 ). Serum samples were obtained from the Medical
and Endocrinology Clinics at Columbia-Presbyterian Medical Center or
from normal individuals (ages 24-69 yr) after obtaining informed con-
sent, according to a protocol approved by the Institutional Review Board.
Assays for VCAM-J. AGE-induced modulation of endothelial
VCAM-1 was studied by assessing binding of Molt-4 cells to ECmono-
layers, by ELISA for cell-associated VCAM-I antigen and in EC super-
natants, by electrophoretic mobility shift assay (EMSA), by Northern
analysis, by nuclear run-on analysis, and by immunostaining following
AGEalbumin infusion into mice.
Molt4-EC binding assays. Molt-4 EC binding assays were per-
formed by the general method of Marui et al. (20). ECs, grown to
confluence in 0.38 cm2 wells, were washed twice in Medium 199 con-
taining fetal bovine serum (1%) and then exposed to either AGEalbu-
min or native albumin for the indicated time at 37TC. Where indicated,
ECs were pre-treated with one of the following: N-acetylcysteine (NAC;
30 mMfor 60 min), cycloheximide (50 ,g/ml for 60 min), anti-RAGE
F(ab')2 (2 pg/ml for 3 h), nonimmune F(ab')2 (2 ,jg/ml for 3 h), or
anti-VCAM-l F(ab')2 (10 jig/ml or 0.1 jig/ml for 30 min). F(ab')2
fragments prepared from murine monoclonal antibody to VCAM-1
(2G7) were generously provided by Dr. Walter Newmanand Dawson
Beall (Otsuka, America, Rockville, MD) (21). Purified recombinant
tumor necrosis factor-alpha (generously provided by Knoll Pharmaceu-
ticals, Whippany, NJ, 108 U/mg) was added to other EC cultures as a
positive control (20). Molt-4 cells (purchased from American Type
Cell Culture, Rockville, MD), which express very late antigen-4 (22),
were grown in RPMI 1640 containing fetal bovine serum (10%). Radio-
labelling was accomplished by incubating Molt-4 cells (2 x 107 cells/
ml) for 16 h at 37°C in the above medium containing 5tCr (0.2 mCi/ml).
Before the binding assay, nonincorporated radioactivity was removed
by washing cells twice with Hanks balanced salt solution, and then
resuspending them in RPMI containing fetal bovine serum (10%) at 4
X 106 cells/ml. Molt-4 cells were incubated with ECs for 1 h at 37°C,
and nonadherent cells were removed by washing twice with Medium
199 containing fetal bovine serum (1%), adherent cells were solubilized
in SDS (1%), and radioactivity was determined. Where indicated, re-
sults are expressed as percent above control compared with Molt-4
binding to ECs treated with native, nonglycated albumin (which was
identical to findings with incubation buffer control alone).
ELUSA. ELISA for human VCAM-1 was performed using a kit from
British Bio-technology Products (Abingdon, Oxon, UK) according to
the manufacturer's instructions. The limit of detection in this assay is
< 2 ng/ml. Where indicated, human umbilical vein endothelial cells
(ECs) or human aortic endothelial cells were treated with the indicated
reagents in Medium 199 containing fetal bovine serum (1%). At the
conclusion of the experiments, culture supernatants were collected and
subjected to 10-fold concentration using Centricon-10 membranes
(Amicon, Beverly MA) and assayed for VCAM-1 antigen by placing
equal volumes of concentrated supernatant per well. For assay of cell-
associated VCAM-1 antigen or ICAM-1 antigen, cells were washed
twice with phosphate-buffered saline, scraped into buffer containing tris
20 mM(pH 7.4), NaCl (0.1 M), PMSF(0.002 M) and octyl-f3-gluco-
side (1%) (Boehringer-Manheim, Indianapolis IN), rocked at 4°C for
4 h, and then centrifuged at 11,000 g for 20 min. The supernatant
was collected and protein concentration determined using the Bradford
reagent (Bio-Rad, Richmond, CA). For ELISA of cell lysates, 0.75 mg
of protein was added to each well. Where indicated, EC monolayers
were pretreated with cycloheximide (50 /Ag/ml for 60 min), anti-RAGE
IgG (30 jig/ml for 3 h), nonimmune IgG (30 ug/ml for 3 h), or N-
acetylcysteine (30 mMfor 60 min). Determination of soluble ICAM-
1 used a commercially available ELISA according to the manufacturer's
instructions (British Biotechnology Products, Abingdon, Oxon, UK).
The limit of detection in this assay is < 2.5 ng/ml. Where indicated,
results are expressed as fold increase above control compared with
elaboration of cellular or supernatant VCAM-1 antigen or ICAM-1 anti-
gen from ECs treated with native, nonglycated albumin (which was
identical to results obtained with incubation buffer control alone). Deter-
mination of plasma AGElevels was determined by ELISA according
to previously published methods (18, 19).
Northern blotting. RNAprepared from cultured ECs (108 cells)
using the guanidinium thiocyanate procedure (23) was applied to agar-
ose-formaldehyde gels (0.8%; 30 ,g), and transferred to nylon filters.
Filters were prehybridized for 1 h at 680C with QUIK Hyb buffer
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(Stratagene, La Jolla, CA) and hybridized in QUIK Hyb buffer for 3 h
at 680C in the presence of 32P-labeled full-length human VCAM-1cDNA
(24) labeled by the random primer procedure. Filters were then washed
with SSC (2x) containing SDS(0.1%) twice for 15 min each at room
temperature, washed again with SSC (0.1x) containing SDS (0.1%)
for 30 min at 550C, dried and subjected to autoradiography. To assess
RNAloading, filters were also hybridized with random primer labeled
32P-cDNA for glyceraldehyde phosphate dehydrogenase (GAPDH) us-
ing the same washing and hybridization procedure.
Nuclear run-on transcription assay. Nuclear run-on transcription
assay was performed using a modification of the methods as described
by Santisteban et al. (25). ECs were incubated with AGEalbumin (100
sg/ml) or native albumin (100 ug/ml) for 6 h at 37TC. Monolayers
were then washed twice with cold phosphate-buffered saline, scraped,
and cell pellets prepared. Pellets were then resuspended in 10 ml of
lysis buffer containing Tris (0.01 M, pH 7.4), NaCl (10 mM), MgCl2
(3 mM), Nonidet P40 (0.5% [vol/vol]), leupeptin (50 sg/ml), dithio-
threitol (1 mM), phenylmethylsulfonyl fluoride (0.5 mM), and aproti-
nin (100 sg/ml), incubated for 15 min on ice, and centrifuged at 500
g for 5 min at 40C. The nuclear pellets were washed once with lysis
buffer as above (4 ml) and centrifuged at 500 g for 5 min at 4TC.
Supernatants were discarded and nuclei resuspended in 0.2 ml reaction
buffer containing Tris (10 mM, pH 8.0), MgCl2 (5 mM), KCl (300
mM), dithiothreitol (1 mM), ATP (0.5 mM), CTP(0.5 mM), GTP(0.5
mM), and 200 microcurie of [a-32P]UTP (3,000 Ci/mmol; Amersham,
Arlington Heights, IL), and reacted at 30°C for 1 h. RNAwas extracted
as above and samples resuspended in hybridization buffer containing
PIPES (50 mM, pH 6.8), EDTA (10 mM), NaCl (600 mM), SDS
(0.2%), and denatured salmon test DNA(100 ,g/ml). Hybridization
to denatured human VCAM-1 and f-actin DNAslot-blotted on nylon
filters was performed at 42°C for 72 h after prehybridization at 80°C
for 2 h in hybridization buffer as above containing 0.1% SDS. After
hybridization, the filters were washed in SSC (2X) containing SDS
(0.1%) for 1 h three times, briefly air-dried and exposed to autoradio-
graphic film for 4 d. For binding to the nylon filter, the human VCAM
gene DNAand 3-actin gene DNAwere denatured by incubation with
NaOH(0.3 N) for 30 min at 65°C. DNAwas spotted onto the nylon
filter and cross-linked with a UV cross-linker (Stratagene).
Electrophoretic mobility shift assays (EMSA). Nuclear extracts were
prepared from ECs by the method of Schreiber et al. (26). Protein
concentration was determined using the Bradford reagent as above.
Double-stranded oligonucleotides representing a portion of the human
VCAM-1 promoter containing an NF-kB site or a mutant NF-kB site
were synthesized (GenSet, Paris, France) (24). Oligonucleotides were
used as probes as follows: NF-kB: S 'CCl'lGAAGGGATTTC-
CCTCC3' and a mutated, inactive form 5'CCTITGAA1TATTA A-
AATCC3' (24). Probes were 5' end-labeled with y_ [32p] ATP and
polynucleotide kinase. Each reaction contained 10 fmol of probe and
2-5 Al (1.5 ug protein) of nuclear extract. Binding reactions were
performed in HEPES50 mM(pH 7.9), glycerol (5%), KCl (5 mM),
MgCl2, dithiothreitol (1 mM), and poly (dI-dC; 1 Ag) in a reaction
volume of 20 Al for 20 min at room temperature. Complexes were
resolved on nondenaturing polyacrylamide gels (6%) in Tris (50 mM),
borate (45 mM), and EDTA (0.5 mM), (0.5X TBE buffer; final pH
7.5). Samples were subjected to electrophoresis for 2 h at 10 V/cm,
gels were then dried and subjected to autoradiography. For supershift
assays, complexes were preincubated for 2 h at 4°C with 7.5 Ag/ml of
anti-p65 IgG, anti-pSO IgG (Santa Cruz Biotechnology, Santa Cruz
CA), both together, or nonimmune IgG, in a total reaction volume of
20 AL
Immunostaining. Immunostaining for VCAM-1 was performed on
lung tissue which had been placed in freezing medium (Polysciences,
Inc., Warrington, PA) and snap frozen in dry ice/methanol for sec-
tioning. Sections were incubated in blocking buffer (phosphate-buffered
saline/bovine serum albumin [1%]/normal rabbit serum [4%]), and
then exposed for 45 min at 37°C to monoclonal rat anti-murine VCAM-
1 IgG (20 sg/ml; Southern Biotechnologies, Birmingham, AL). Pri-
mary antibody was revealed with rabbit anti-rat Extra Avidin (Sigma
Chemical Co.) using acetylethylcarbazole as the chromogen.
Results
Exposure of cultured human ECs to AGEs increases their ad-
hesivity for Molt-4 cells and expression of VCAM-J. ECmono-
layers incubated with AGEalbumin exhibited time-dependent
enhancement of Molt-4 binding (these cells bear the counter
ligand for VCAM-1, very late antigen 4 (VLA-4; 22); which
was maximal at 2 h (Fig. 1 A) and gradually fell to the baseline
by 12 h (data not shown). AGE-enhanced binding of Molt-4
cells to endothelium was prevented by blocking with F(ab')2
against VCAM-1, suggesting a central role for VCAM-1 as the
EC adherence molecule mediating this interaction (Fig. 1 B).
De novo endothelial protein synthesis was required to support
Molt-4 binding, as preincubation of endothelium with cyclohex-
imide was inhibitory (Fig. 1 B). Molt-4 binding to AGE-treated
ECs was not due to passive adsorption of the glycated protein
to the endothelial surface because affinity-purified antibody to
AGEs, which prevents their cellular interactions (18, 19), had
no effect when added during the adherence assay (data not
shown).
In parallel with increased VCAM-1-dependent binding of
Molt-4 cells to AGE-treated endothelium, expression of
VCAM-1 antigen by ECs was enhanced as measured by ELISA
(Fig. 2 A); this occurred in a time-dependent manner similar
to that observed for Molt-4 binding to AGE-treated endothelium
(data not shown). Enhancement of cellular VCAM-I expres-
sion by AGEswas prevented by addition of cycloheximide (Fig.
2 A), consistent with results of cell adherence experiments (Fig.
1 B). AGEs obtained from diabetic serum (18) also enhanced
EC expression of VCAM-1 (Fig. 2 A), indicating that AGE-
adducts generated in vivo had similar properties, with respect
to endothelial VCAM-I expression, compared to AGEalbumin
prepared in vitro. In contrast, AGE-depleted serum was without
effect (Fig. 2 A). The effect of AGEs on VCAM-I expression
was selective, as there was no change in EC levels of ICAM-
1 as measured by ELISA after treatment with AGEalbumin
(Fig. 2 B), whereas tumor necrosis factor-a, added as a positive
control, significantly increased ICAM-1 expression (27). Hu-
man aortic vein endothelial cells were also tested for their re-
sponse to AGEs since they more closely approximate the endo-
thelial cells likely to be relevantly affected in in vivo models
of atherosclerosis. When human aortic endothelial cells were
exposed to AGEalbumin, expression of cellular VCAM-1 anti-
gen was increased as measured by ELISA (Fig. 2 C) whereas
native albumin was without effect (Fig. 2 C).
Consistent with possible AGE-induced de novo synthesis
of VCAM-1, levels of VCAM-1 mRNAwere elevated in ECs
exposed to AGEalbumin, whereas transcripts for GAPDHwere
unchanged (Fig. 2 D). Nuclear run-on transcription assay indi-
cated that this was due to increased transcription of mRNAfor
VCAM-1 in AGE-treated ECs (Fig. 2 E).
Mechanisms underlying AGE-induced EC expression of
VCAM-1. Previous studies have shown that RAGEis present
in ECs, both in vitro and in vivo, and that it is the principal
binding site on endothelium for AGEs (11). To determine if
AGE-RAGEinteraction-mediated VCAM-1 induction, access
to RAGEwas blocked with monospecific antibody to RAGE,
and with sRAGE, the latter a truncated form of full-length
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Figure 1. Exposure of ECs to
AGEalbumin enhances their ad-
hesivity for Molt-4 cells. (A) ECs
were incubated for the indicated
times with AGEalbumin (100 Mig1
ml) or nonglycated albumin (100
pg/ml) at 37TC as shown, washed,
and then a binding assay was per-
formed with 5"Cr-labeled Molt-4
cells. (B) ECs were incubated
with AGEalbumin (100 pg/ml),
washed, and then a Molt-4 binding
assay was performed. Where indi-
cated, ECs were pretreated with
anti-VCAM-1 F(ab')2 for 30 min
immediately before the Molt-4
binding assay; or the endothelium
was pretreated with cyclohexi-
mide (50 ag/ml for 1 h) before
exposure to AGEalbumin. In each
case, the mean±SEMof at least
triplicate determinations is shown.
In A, * denotes P < 0.01 com-
pared with native albumin using
the student's unpaired t test. In B,
* and ** denote P < 0.01 and P
< 0.001, respectively, compared
with treatment with AGEalbumin
alone using the student's unpaired
t test.
RAGEcomprising the extracellular domain (11-13). Pre-incu-
bation of ECs with anti-RAGE F(ab ' )2 largely prevented AGE-
mediated increased endothelial adherence of Molt-4 cells (Fig.
3 A) and anti-RAGE IgG blocked the increase in VCAM-1
antigen completely (Fig. 3 B), whereas nonimmune reagents
had no effect (Fig. 3, A and B). sRAGEhad a similar, though
even more complete (> 95%) inhibitory effect on the binding
of Molt-4 cells to AGE-treated ECs and their expression of
VCAM-1 (Fig. 3, A and B). These data indicated that AGE-
RAGEinteraction had a central role in AGEinduction of endo-
thelial VCAM-1.
AGEstethered to cell surface RAGEinduce cellular oxidant
stress; this assertion is based on several lines of evidence, in-
cluding generation of thiobarbituric acid-reactive substances,
expression of heme oxygenase type I mRNA, and activation of
the transcription factor NF-kB ( 19). NF-kB sites in the VCAM-
1 promoter have been shown to participate in regulation of
VCAM-1 expression in response to cytokines, mediated, at least
in part, by an oxidant mechanism impacting on activation of
NF-kB (20, 24, 28). These data led us to examine if AGE-
induced cellular oxidant stress was involved in up-regulating
VCAM-1 expression. Pretreatment of endothelium with the an-
tioxidant N-acetylcysteine inhibited AGE-enhanced Molt-4
binding (Fig. 3 A) as well as enhanced expression of VCAM-
1 antigen (Fig. 3 B). In addition, AGEbinding to endothelial
RAGEtriggered events resulting in expression of DNAbinding
activity for the NF-kB site in the VCAM-1 promoter. Activation
of NF-kB, by incubating the ECs with TNF-a, served as a
positive control in this experiment (Fig. 3 C, lane 1). After
exposure of ECs to AGEalbumin, EMSAdemonstrated a gel
shift band (Fig. 3 C, lanes 3, 6, and 10) not observed with
cultures exposed to native albumin (Fig. 3 C, lane 2). AGE-
induced DNA binding activity was sequence specific, as its
appearance was blocked by excess unlabelled NF-kB probe, but
was not affected by a mutationally inactivated NF-kB probe
(Fig. 3 C, lanes 4 and 5, respectively). DNAbinding activity
was probably dependent on p50 and p65 proteins of the NF-kB
family in the nucleus, as indicated by the distinct retardation
patterns of AGE-induced gel shift bands in the presence of anti-
p65 IgG (Fig. 3 C, lane 7), anti-p5O IgG (Fig. 3 C, lane 8) or
in the presence of both antibodies (Fig. 3 C, lane 9), suggesting
the involvement of both the p50 and p65 proteins of the NF-
kB family. The same concentration of nonimmune IgG was
without effect (data not shown). NF-kB activation was largely
inhibited by the higher concentration of anti-RAGE IgG, 70
pg/ml (Fig. 3 C, lane 11) whereas a lower concentration of
anti-RAGE IgG, 0.7 a.tg/ml had no effect (Fig. 3 C, lane 12).
In contrast, nonimmune IgG did not alter intensity of the AGE-
induced gel shift band (Fig. 3 C, lane 13). NF-kB activation by
AGEalbumin was also inhibited by addition of N-acetylcysteine
(Fig. 3 C, lane 14). These data indicate that AGEbinding to
endothelial RAGEactivates nuclear binding activity for the
VCAM-1 NF-kB site, likely via an oxidant mechanism. Consis-
tent with these data, elevated levels of VCAM-1 transcripts in
AGE-treated ECs were blocked in the presence of anti-RAGE
IgG, but not with nonimmune IgG (Fig. 3 D, lanes 2 and 3,
respectively), and by N-acetylcysteine (data not shown).
Infusion of AGEs induces VCAM-J in mice and patients
with diabetes display increased expression of soluble VCAM-
1. In view of the association of AGEs and oxidant stress with
diabetes (8), we considered whether induction of VCAM-1
might occur in diabetic vasculature. To approach this question,

























CHX- Patient Patient Native AGE ThF-a
AGE Pdbumin AGEs AGE-Depleted Albumin Albumin
Serum
C
Figure 2. Effect of AGEAlbumin and AGEs from dia-
D L betic plasma on EC expression of VCAM-1. (A) ECs
(human umbilical vein) were incubated for 6 h with
1 2 3 AGEalbumin (100 tig/ml), native, nonglycated albu-
min (100 pg/ml), patient-derived AGEs (10 jg/ml) or
HumanVCAM-1 j3'BACtn patient AGE-depleted serum (this material represented
the pass-through from the anti-AGE IgG Affigel 10
HumanGAPDH resin, thus equivalent volumes to that of patient-derivedAGEs were added to each culture well) at 37TC, and
,, .> .Us ~ CAW then cell-associated ELISA for VCAM-1 antigen was
_ <61 ok performed. Where indicated, cycloheximide (CHX; 50
ok *go<Zasppale ,S~t.> Hg/ml for 1 h) was added prior to EC treatment with
TsAf(I &~s +sF-sp AGEalbumin. The mean±SEMof at least triplicate
determinations is shown. ** above AGEalbumin and
patient AGEs denotes P < 0.001 compared to native
albumin using the student's unpaired t test, and ** above CHX-AGEalbumin denotes P < 0.001 compared with treatment with AGEalbumin
alone using the student's unpaired t test. (B) ECs (human umbilical vein) were incubated for 6 h at 37TC with AGEalbumin (100 jig/ml) or native
albumin (100 jig/ml) and cellular ELISA for ICAM-1 antigen was performed. As indicated, TNF (10 nM) was incubated for 6 h at 37TC with
ECs as a positive control. The mean±SEMof at least triplicate determinations is shown. * denotes P < 0.01 compared with native albumin alone
using the student's unpaired t test. (C) Humanaortic endothelial cells were incubated for 6 h with AGEalbumin (100 jg/ml) or native, nonglycated
albumin at 37TC, and then cell-associated ELISA for VCAM-I antigen was performed. The mean±SEMof at least triplicate determinations is
shown. * * above AGEalbumin indicates P < 0.001 compared to native albumin using the student's unpaired t test. (D) Northern analysis of EC
RNAfor VCAM-1 transcripts: effect of AGEalbumin. ECs were incubated with TNF-a (10 nM) (lane 1) or native nonglycated albumin (100
pHg/ml) (lane 2) or AGEalbumin (100 jig/ml) (lane 3) as indicated for 6 h at 37TC, RNAwas harvested, subjected to electrophoresis, blotted
onto nitrocellulose and hybridization with 32P-labeled cDNAprobes for VCAM-1 or GAPDHperformed as indicated. (E) Nuclear run-on transcription
assay: ECs were treated with AGEalbumin (100 jig/ml) or native albumin (100 jig/ml) for 6 h at 37TC, nuclei isolated and 32P-labeled nuclear
run on products hybridized to denatured human VCAM-1 gene DNAor ,/-actin gene DNAslot-blotted on nylon filters, as described above.
AGEalbumin was infused into normal mice and expression of
VCAM-1 in the vasculature was assessed. After administration
of AGEalbumin, VCAM-1 was identified in murine vasculature
by immunostaining (Fig. 4 B), but was absent in animals in-
fused with native albumin (Fig. 4 A).
These data led us to inquire whether patients with diabetes
might also exhibit increased expression of VCAM-1. In pilot
studies, incubation of AGE albumin with ECs not only led
to increased cell-associated VCAM-1 (Fig. 2 A), but also to
increased soluble(s) VCAM-1 in culture supernatants based on
ELISA (Fig. 4 C); elaboration of sVCAM-1 occurred in a time-
dependent manner parallelling expression of cellular VCAM
(data not shown). Of note, pilot studies revealed that ECsuper-
natants containing sVCAM-1 did not antagonize binding of
Molt-4 cells to stimulated ECs expressing VCAM-1 (data not
shown). These data suggested that sVCAM-1 might serve as a
marker for AGE-induced (and probably the capacity of other
mediators to induce) VCAM-1 expression. sVCAM-l antigen
was measured in patients with a spectrum of diabetic complica-
tions at different stages in the severity of their vascular disease
(Fig. 4 D). Only patients with diminished glomerular filtration
rate were excluded, as sVCAM-1 levels have been shown to be
elevated with renal insufficiency (29). Patients with diabetes
(n = 18) displayed sVCAM-1 levels (mean, 1,115 ng/ml)
1.8-fold higher than that observed in age-matched nondia-
betic controls (mean, 632 ng/ml) (n = 20; P < 0.001 using the
student's unpaired t test). Consistent with these data, diabetic
patients demonstrated higher circulating levels of plasma AGEs
as measured by ELISA (244 ng/ml AGEalbumin equivalents)
than age-matched controls (157 ng/mi AGEalbumin equiva-
lents, P < 0.001 using the student's unpaired t test).
Discussion
Our results indicate that AGEs, aldose-modified proteins present
within the intravascular space and which accumulate in the
vessel wall and other tissues especially in diabetes (7-10),
interact with endothelium to induce VCAM-1, an adhesion mol-
ecule for MPs associated with development of atherosclerosis
(3-6). These data add to a growing body of evidence concern-
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A B Figure 3. AGEalbumin-medi-
100 - 10 ated induction of endothelialVCAM-l: effect of blocking
2g90 access to RAGEon enhanced
C 2~0 80 - 8 - Molt-4 binding (A), enhanced
> 70 _ 7 expression of VCAM-l anti-
60 6 gen (B), activation of NF-kB
Z.!_ < ~~~~~~~~~~~~~~~~~~~~~(C),and enhanced VCAM-1ItF 50 5I I I 111 I 111 | 9 _ | * transcription (D). (A) ECs
40-4-were incubated withAGE a-
I 30 3 - bumin (100 Mig/ml) alone for
20 Z** - 2 -* * 6 h at 37C or in the presence
10 1 ~~~~~~~~~~~~~~~~~~~~~~~Tof nonimmune F(ab')2 (2 Mtg/A7t ] 1 [X.Xml),anti-RAGE F(ab')2 (2
AGE a-RAGE Nonimmune sRAGE NAC AGE a-RAGE Nonimmune sRAGE NAC tg/m1), sRAGE(1500 ,g/
Alburrin F (ab')2 F(ab')2 (30x molar Albumin IgG IgG (30x molar ml) or N-acetylcysteine (30
excess) excess) mM) as above. A binding
AGEAlbumin AGEAlbumin assay was then performed with
5'Cr-labeled Molt4 cells as
C described. The mean±SEMof
at least triplicate determina-
1 2 3 4 5 6 7 8 9 10 11 12 13 14 tions is shown. In all cases,**
denotes P < 0.001 compared
with treatment with AGEalbu-
min alone using the student's
unpaired t test. (B) ECs were
incubated with AGEalbumin
1 2 3 alone or in the presence of
anti-RAGE IgG (30 jig/ml for
HumanVCAM-1 ~~~~~~3h), nonimmune IgG (30 jig/11 1 m ~~~~~HumanVCAM-1 ^** sSos[Gl g ml for 3 h) or N-acetyl cys-
teine (30 mMfor 60 mins) and
cellular ELISA for VCAM-l
HumanGAPDH was performed. In each case,
the mean±SEMof at least
_>(gZi{a,& in,& triplicate determinations is_- m = 0 SpAmshown. ** denotes P < 0.001
< / ,({{compared with treatment with
CY~~~~ C)~AGEalbumin alone using the
_gi_t Q student's unpaired t test. (C)
Binding of EC nuclear pro-
teins to NF-kB binding site in
the VCAM-1 promoter:
EMSA. All lanes contain the
labelled probe. Lanes refer to
samples obtained from: ECs incubated for 6 h at 370C with TNF-a (10 nM, lane 1) nonglycated albumin (100log/ml, lane 2) or with AGEalbumin
(100l g/ml, lanes 3, 6, and JO); nuclear extract from ECs incubated with AGEalbumin preincubated with anti-p5O IgG (lane 8) or anti-p65 IgG
(lane 7) or both anti-p5O IgG and anti-p65 IgG together (lane 9). ECs were either preincubated with anti-RAGE IgG (70 jg/ml or 0.7 jg/ml for
3 h, lanes 11 and 12, respectively) or nonimmune IgG (70 jg/ml for 3 h, lane 13) or N-acetylcysteine (30 mMfor 1 h, lane 14), followed by
treatment with AGEalbumin (100 jig/ml) for 6 h at 370C. After treatment with AGEalbumin for 6 h at 370C, EC nuclear extracts were prepared
and incubated with 32P-labeled NF-kB probe in the presence of an 100-fold molar excess of either unlabelled NF-kB (lane 4) or the mutated NF-
kB probe (lane 5). (D) ECs were incubated with AGEalbumin (100 Mg/ml) (lane 1) for 6 h in the presence or absence of anti-RAGE IgG (30
Mig/ml for 3 h) or nonimmune IgG (30 Mig/ml for 3 h) (lanes 2 and 3, respectively) and then RNAextracted and Northern blotting performed as
above.
ing functional consequences of AGEbinding to RAGE. These phages in response to a gradient of soluble AGEsand inhibition
include increased permeability of ECmonolayers (30); changes of migration when a deposit of immobilized AGEs is encoun-
in cell surface coagulant properties with induction of low levels tered (18, 31, 32). Expression of VCAM-1 by ECs in response
of tissue factor procoagulant activity (30); and receptor-medi- to AGE albumin probably underlies the enhanced monocyte
ated transcytosis and delivery of the glycated ligand to the binding followed by transmigration through EC monolayers
subendothelium (14) where it permits interaction with smooth grown on filters with AGEs in the lower compartment ( 18, 31 ).
muscle cells. AGE-mediated induction of VCAM-1 also eluci- This suggests the possibility that AGEs within the vessel wall
dates an evolving picture in which the glycated ligand stimulates (33) could stimulate overlying endothelium to produce VCAM-
cytokine and growth factor production, and modulates macro- 1, thereby targeting MPs to the vessel surface. Such AGEs,
phage migration. There is accelerated chemotaxis of macro- which are present for long times within the vessel wall, might
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have a more sustained effect on EC expression of VCAM-1
and/or could magnify effects of other stimuli which modulate
endothelial VCAM-1 production, such as cytokines (27). Thus,
measurement of circulating (plasma) AGElevels may only be
partially relevant given the likely diffuse distribution of patho-
genic irreversibly-glycated proteins in the vasculature, only
some of which may be readily amenable to isolation and analy-
sis pre-mortem.
Although AGEs comprise a class of heterogeneous struc-
tures, their interactions with endothelium appear to be mediated
mostly via RAGE (11-12). In the current studies, either
blocking antibody/F(ab')2 or sRAGE inhibited induction of
VCAM-1 at the same concentrations that blocked binding of
AGEalbumin to the EC surface. Interaction of AGEalbumin
with MPs, as well as their interaction with other AGE-modified
proteins (34), has been shown similarly to involve RAGE,
suggesting that this receptor is a major site for cell surface
AGE-mediated events although other AGEcellular binding sites
may also be present (35, 36). VCAM-1 expression appears to
be induced by generation of cellular oxidant stress consequent
on cell surface AGE-RAGEinteraction. This could arise from
ROls produced by the glycated proteins themselves (8, 37-
40) and/or receptor-mediated triggering of signal transduction
mechanisms leading to low levels of oxygen-free radical pro-
duction (20, 24, 41-43). Specific signal transduction mecha-
nisms activated by AGE-RAGEinteraction have not been
mapped in detail, but based on the presence of a short, highly








Figure 4. AGEalbumin infusion induces vascular ex-
pression of VCAM-1 (A and B), release of sVCAM-1
from cultured ECs (C), and sVCAM-1 is present in
diabetic plasma (D). (A-B) Mice were infused with
either nonglycated albumin (500 jig/animal; A) or AGE
albumin (500 jig/animal; B) and 6 h later lung was
harvested and immunostaining with anti-murine
VCAM-1 antibody was performed. Magnification:
x340. (C) ECs were incubated with AGEalbumin (100
jig/ml) or nonglycated albumin (100 jig/ml) for 6 h at
37°(, culture supernatant was collected, concentrated
10-fold, and assayed for VCAM-1 antigen by ELISA.
The mean±SEMof at least triplicate determinations is
shown. * * denotes P < 0.001 using the student's un-
paired t test. (D) Plasma from patients with diabetes (n
= 18) or normal controls (n = 20) was obtained and
assayed for VCAM-1 antigen or AGEalbumin equiva-
lent by ELISA. For sVCAM-1, values are 1,115 ng/ml
(SD = 469 ng/ml) for diabetic patients and 632 ng/ml
(SD = 115 ng/ml) for age-matched controls. For AGE
levels, values are 244 ng/ml AGEalbumin equivalents
(SD = 27 ng/ml AGEalbumin equivalents) for diabetic
patients and 157 ng/ml AGEalbumin equivalents (54
= ng/ml AGEalbumin equivalents). In both cases, * *
denotes P < 0.001 using the student's unpaired t test.
pothesize that ligand-receptor interaction allows the cytosolic
tail to bind intracellular polypeptides which participate in sig-
naling. These observations support the concept that RAGEis
not a simple scavenger receptor which rapidly endocytoses and
degrades AGEs, thereby clearing tissues of aldose-modified
polypeptides or lipids; rather, engagement of the ligand sets in
motion events which lead to a spectrum of changes in cellular
properties. In view of the potentially injurious nature of subse-
quent cellular events following AGE-RAGE interaction, it
seems probable that AGEs are accidental ligands of RAGE, a
receptor meant to recognize other ligands in quite different
settings. Such a role for RAGEother than binding to AGEs is
supported by evidence of enhanced RAGEexpression in the
central nervous system in early development and in some types
of mature neurons, and its strong constitutive expression in
smooth muscle cells (15; data not shown).
The observation that the AGE-RAGEinteraction induces
cell-associated VCAM-1, and also releases sVCAM-l antigen
into culture supernatants, suggests a means of monitoring this
event in vivo. Furthermore, increased levels of sVCAM-1 were
observed in diabetic patients compared with a range of normal
controls. Although the functional significance of sVCAM-l is
at present unclear (pilot studies have shown lack of antagonism
of Molt-4 binding to EC surface VCAM-1), sVCAM-1 could
serve as a marker of vascular perturbation in diabetes. Since
endothelial expression of VCAM-1 occurs in response to di-
verse stimuli, including cytokines (27), and could result from
the oxidant stress consequent on hyperglycemia itself (44),
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plasma VCAM-1 levels are likely to reflect the complexity of
events which occur within the vasculature in vivo. Even with
these diverse stimuli for induction of VCAM-1 in diabetes, we
hypothesize that serial sVCAM-1 levels could be of benefit in
identifying patients at high risk for the development of clinically
apparent vascular complications (as a result of ECperturbation
due to AGEs or other agents) and might provide a surrogate
marker for assessment of therapy designed to attenuate the pro-
gression of vascular disease.
Taken together with our recent demonstration that AGEs
induce expression by smooth muscle cells of the chemotactic
polypeptide JE/MCP-1 (45), these data suggest a pathway
through which AGEs attract monocytes to bind to the vessel
surface, followed by their migration into the vessel wall and
subsequent stimulation with production of mediators potentially
contributing to the development of vascular lesions. The recent
observation of increased VCAM-1 expression in diabetic rabbits
(5) and our finding of elevated sVCAM-1 levels in diabetic
patient plasma suggests that this cell adherence molecule might
have a important role in the pathogenesis of diabetic vascular
disease.
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